Sienna Biopharmaceuticals, Inc. (OTCMKTS:SNNAQ) Sees Large Increase in Short Interest

Sienna Biopharmaceuticals, Inc. (OTCMKTS:SNNAQ) was the recipient of a significant increase in short interest in May. As of May 28th, there was short interest totalling 20,400 shares, an increase of 1,100.0% from the May 13th total of 1,700 shares. Based on an average daily volume of 36,100 shares, the days-to-cover ratio is presently 0.6 days.

SNNAQ stock traded up $0.00 during mid-day trading on Friday, reaching $0.03. The company had a trading volume of 1,800 shares, compared to its average volume of 102,355. The stock’s 50 day moving average is $0.03. Sienna Biopharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.07.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Recommended Story: G-20

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.